Margaret K Callahan

List of Publications by Year
in descending order

63 papers	22,817 citations	126907 33 h-index	189892 50 g-index
65 all docs	65 docs citations	65 times ranked	29229 citing authors

#	Article	IF	Citations
1	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New England Journal of Medicine, 2015, 373, 23-34.	27.0	6,773
2	Nivolumab plus Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2013, 369, 122-133.	27.0	3,776
3	Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma. New England Journal of Medicine, 2012, 366, 925-931.	27.0	1,836
4	OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology, 2017, 2017, 1-16.	3.0	1,266
5	Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. Journal of Clinical Oncology, 2015, 33, 3193-3198.	1.6	892
6	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell, 2018, 33, 843-852.e4.	16.8	827
7	Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nature Communications, 2016, 7, 10391.	12.8	784
8	Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell, 2018, 33, 853-861.e4.	16.8	725
9	Immune-related adverse events of checkpoint inhibitors. Nature Reviews Disease Primers, 2020, 6, 38.	30.5	684
10	Hepatotoxicity with Combination of Vemurafenib and Ipilimumab. New England Journal of Medicine, 2013, 368, 1365-1366.	27.0	655
11	Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncology, The, 2016, 17, 1590-1598.	10.7	594
12	Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody. Science Translational Medicine, 2014, 6, 230ra45.	12.4	526
13	Targeting T Cell Co-receptors for Cancer Therapy. Immunity, 2016, 44, 1069-1078.	14.3	418
14	Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. Journal of Clinical Oncology, 2018, 36, 1685-1694.	1.6	399
15	Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment. New England Journal of Medicine, 2012, 367, 2316-2321.	27.0	222
16	Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nature Medicine, 2020, 26, 1114-1124.	30.7	216
17	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nature Medicine, 2021, 27, 1432-1441.	30.7	216
18	Antiâ€"CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy. Seminars in Oncology, 2010, 37, 473-484.	2.2	208

#	Article	IF	Citations
19	Initial efficacy of anti-lymphocyte activation gene-3 (antiâ€“LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with antiâ€“PD-1/PD-L1 therapy.. Journal of Clinical Oncology, 2017, 35, 9520-9520.	1.6	188
20	CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. Frontiers in Oncology, 2014, 4, 385.	2.8	175
21	Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. Journal of Clinical Oncology, 2018, 36, 391-398.	1.6	156
22	Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. Oncologist, 2016, 21, 848-854.	3.7	154
23	On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Science Translational Medicine, 2015, 7, 280sr1.	12.4	134
24	Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma. JAMA Oncology, 2018, 4, 98.	7.1	125
25	Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor. Cancer Immunology Research, 2014, 2, 70-79.	3.4	100
26	Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response. Head and Neck, 2016, 38, 1310-1317.	2.0	65
27	Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child. Nature Medicine, 2021, 27, 1646-1654.	30.7	65
28	Immunomodulatory therapy for melanoma: Ipilimumab and beyond. Clinics in Dermatology, 2013, 31, 191-199.	1.6	57
29	Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab. Journal of the National Cancer Institute, 2017, 109, djw260.	6.3	56
30	LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. Science Translational Medicine, 2021, 13, .	12.4	54
31	Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. Annals of Surgical Oncology, 2020, 27, 1180-1188.	1.5	39
32	Checkpoint Blockade for the Treatment of Advanced Melanoma. Cancer Treatment and Research, 2016, 167, 231-250.	0.5	36
33	Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade. Gynecologic Oncology, 2019, 152, 251-258.	1.4	33
34	Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience. Oncologist, 2019, 24, e196-e197.	3.7	31
35	Summary and Recommendations from the National Cancer Instituteâ€™s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer, 2016, 2, 165-202.	0.4	30
36	Recruit or Reboot? How Does Anti-PD-1 Therapy Change Tumor-Infiltrating Lymphocytes?. Cancer Cell, 2019, 36, 215-217.	16.8	29

#	Article	IF	Citations
37	<i>BRCA</i> Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer. JCO Precision Oncology, 2020, 4, 665-679.	3.0	29
38	The Antitumor Immunity of Ipilimumab: (T-cell) Memories to Last a Lifetime?. Clinical Cancer Research, 2012, 18, 1821-1823.	7.0	27
39	Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. , 2021, 9, e001884.		27
40	Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas. Clinical Cancer Research, 2021, 27, 2226-2235.	7.0	25
41	Safety of Infusing Ipilimumab Over 30 Minutes. Journal of Clinical Oncology, 2015, 33, 3454-3458.	1.6	24
42	Fundamental immuneâ€"oncogenicity trade-offs define driver mutationÂfitness. Nature, 2022, 606, 172-179.	27.8	23
43	Clinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists. Seminars in Oncology, 2015, 42, 573-586.	2.2	21
44	Checkpoint Modulation in Melanoma: An Update on Ipilimumab and Future Directions. Current Oncology Reports, 2013, 15, 500-508.	4.0	20
45	Evaluation of the absolute lymphocyte countÂas a biomarker for melanoma patients treated with the commercially available dose of ipilimumab (3mg/kg).. Journal of Clinical Oncology, 2012, 30, 8575-8575.	1.6	16
46	Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. , 2022, 10, e003853.		16
47	Implanted Hepatic Arterial Infusion Pumps. Cancer Journal (Sudbury, Mass), 2010, 16, 142-149.	2.0	12
48	Immune Checkpoint Therapy in Melanoma. Cancer Journal (Sudbury, Mass), 2016, 22, 73-80.	2.0	10
49	Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab. , 2021, 9, e003395.		7
50	Clinical implications of drugâ€induced liver injury in earlyâ€phase oncology clinical trials. Cancer, 2020, 126, 4967-4974.	4.1	6
51	Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy. Gynecologic Oncology, 2020, 158, 303-308.	1.4	4
52	Two Drugs Are Better than Oneâ€"Modeling Drug Combinations in Cancer Therapy. Science Translational Medicine, 2013, 5, .	12.4	3
53	Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma. Cancer Immunology Research, 2022, 10, 303-313.	3.4	1
54	Reply to A. Indini et al. Journal of Clinical Oncology, 2016, 34, 1018-1019.	1.6	0

#	Article	IF	Citations
55	Apples and Oranges? Considerations for EHR-Based Analyses Aggregating Data From Interventional Clinical Trials and Point-of-Care Encounters in Oncology. JCO Clinical Cancer Informatics, 2021, 5, 21-23.	2.1	0
56	Gut Reaction: Microbiome Provides a Clue to Gender Bias in Autoimmunity. Science Translational Medicine, 2013, 5, .	12.4	0
57	Uncovering a Hidden Talent. Science Translational Medicine, 2013, 5, .	12.4	0
58	T Cells Take Notice of Distinct Mutations in Cancer Cells. Science Translational Medicine, 2013, 5, .	12.4	0
59	New MEK-anisms for Targeted Therapies. Science Translational Medicine, 2013, 5, .	12.4	0
60	EGFR Mutations Transform Tumors Inside and Out. Science Translational Medicine, 2013, 5, .	12.4	0
61	Searching for Needles in the T Cell Receptor Haystack. Science Translational Medicine, 2013, 5, .	12.4	0
62	Oncogene Addiction: How Cells Handle the Habit. Science Translational Medicine, 2014, 6, .	12.4	0
63	Seeking Harmony Among Cancer Killers. Science Translational Medicine, 2014, 6, .	12.4	0